OXB Stock Overview
Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various diseases in Europe and internationally.
Oxford Biomedica Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||UK£13.56|
|52 Week High||UK£16.78|
|52 Week Low||UK£8.10|
|1 Month Change||-10.91%|
|3 Month Change||-8.50%|
|1 Year Change||56.76%|
|3 Year Change||89.65%|
|5 Year Change||604.42%|
|Change since IPO||-46.30%|
Recent News & Updates
|OXB||GB Biotechs||GB Market|
Return vs Industry: OXB exceeded the UK Biotechs industry which returned 24.6% over the past year.
Return vs Market: OXB exceeded the UK Market which returned 11.6% over the past year.
|OXB Average Weekly Movement||5.6%|
|Biotechs Industry Average Movement||5.9%|
|Market Average Movement||4.9%|
|10% most volatile stocks in GB Market||9.7%|
|10% least volatile stocks in GB Market||2.6%|
Stable Share Price: OXB is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: OXB's weekly volatility (6%) has been stable over the past year.
About the Company
Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various diseases in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates multiple therapeutic genes.
Oxford Biomedica Fundamentals Summary
|OXB fundamental statistics|
Is OXB overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|OXB income statement (TTM)|
|Cost of Revenue||UK£69.71m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.21|
|Net Profit Margin||13.71%|
How did OXB perform over the long term?See historical performance and comparison
Is Oxford Biomedica undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: OXB (£13.56) is trading above our estimate of fair value (£1.33)
Significantly Below Fair Value: OXB is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: OXB's PE Ratio (63.1x) is in line with the UK Biotechs industry average.
PE vs Market: OXB is poor value based on its PE Ratio (63.1x) compared to the UK market (19.2x).
Price to Earnings Growth Ratio
PEG Ratio: OXB's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: OXB is overvalued based on its PB Ratio (8.8x) compared to the GB Biotechs industry average (6.3x).
How is Oxford Biomedica forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OXB's earnings are forecast to decline over the next 3 years (-12.8% per year).
Earnings vs Market: OXB's earnings are forecast to decline over the next 3 years (-12.8% per year).
High Growth Earnings: OXB's earnings are forecast to decline over the next 3 years.
Revenue vs Market: OXB's revenue is expected to decline over the next 3 years (-4.2% per year).
High Growth Revenue: OXB's revenue is forecast to decline over the next 3 years (-4.2% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: OXB's Return on Equity is forecast to be low in 3 years time (4.6%).
How has Oxford Biomedica performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: OXB has high quality earnings.
Growing Profit Margin: OXB became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: OXB has become profitable over the past 5 years, growing earnings by 28.9% per year.
Accelerating Growth: OXB has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: OXB has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (50.7%).
Return on Equity
High ROE: OXB's Return on Equity (14%) is considered low.
How is Oxford Biomedica's financial position?
Financial Position Analysis
Short Term Liabilities: OXB's short term assets (£123.9M) exceed its short term liabilities (£47.3M).
Long Term Liabilities: OXB's short term assets (£123.9M) exceed its long term liabilities (£17.8M).
Debt to Equity History and Analysis
Debt Level: OXB is debt free.
Reducing Debt: OXB has no debt compared to 5 years ago when its debt to equity ratio was 336.6%.
Debt Coverage: OXB has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: OXB has no debt, therefore coverage of interest payments is not a concern.
What is Oxford Biomedica current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate OXB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate OXB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if OXB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OXB's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of OXB's dividend in 3 years as they are not forecast to pay a notable one for the UK market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
John Dawson (61 yo)
Mr. John Dawson has been the Chief Executive Officer of Oxford BioMedica PLC since October 13, 2008. Mr. Dawson has broad experience in European commercial activities, finance and in mergers and acquisitio...
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD1.67M) is about average for companies of similar size in the UK market ($USD1.53M).
Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.
Experienced Management: OXB's management team is considered experienced (3.4 years average tenure).
Experienced Board: OXB's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: OXB insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.7%.
Oxford Biomedica plc's employee growth, exchange listings and data sources
- Name: Oxford Biomedica plc
- Ticker: OXB
- Exchange: LSE
- Founded: 1995
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: UK£1.167b
- Shares outstanding: 86.09m
- Website: https://www.oxb.com
Number of Employees
- Oxford Biomedica plc
- Windrush Court
- Transport Way
- OX4 6LT
- United Kingdom
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/11/29 22:53|
|End of Day Share Price||2021/11/29 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.